Bayer struck an US$875 million deal to acquire British women’s health biotech Kandy Therapeutics, bolstering its pharmaceuticals division before patents expire on some key products.
The German drug and chemical company agreed to pay US$425 million upfront and potential milestone payments of US$450 million until the launch of Kandy’s experimental treatment for menopause symptoms, reported Bloomberg.
Kandy’s drug NT-814 is expected to start a final-stage clinical trial next year and could generate peak sales of €1 billion (US$1.17 billion) globally, Bayer said Tuesday, August 11, in a statement. Bayer rose as much as 1.8% in Frankfurt.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI